TWD 65.1
(-0.61%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 315.74 Million TWD | -18.17% |
2022 | 385.85 Million TWD | 138.52% |
2021 | 161.77 Million TWD | -14.02% |
2020 | 188.15 Million TWD | -24.53% |
2019 | 249.32 Million TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 25.96 Million TWD | 0.0% |
2024 Q1 | 25.96 Million TWD | 0.0% |
2023 Q4 | 315.74 Million TWD | 0.0% |
2023 Q2 | 360.91 Million TWD | 0.0% |
2023 Q1 | 360.91 Million TWD | -6.46% |
2023 FY | 315.74 Million TWD | -18.17% |
2023 Q3 | 315.74 Million TWD | -12.52% |
2022 Q3 | 385.85 Million TWD | 0.0% |
2022 Q4 | 385.85 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Allied Biotech Corporation | 72.02 Million TWD | -338.394% |
GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | -314.646% |
Easywell Biomedicals, Inc. | 330.44 Million TWD | 4.448% |
TTY Biopharm Company Limited | 403.04 Million TWD | 21.66% |
Synmosa Biopharma Corporation | 1.45 Billion TWD | 78.354% |
Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | 85.667% |
Center Laboratories, Inc. | 4.42 Billion TWD | 92.871% |
Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | -83653.05% |
Orient Pharma Co., Ltd. | 323.73 Million TWD | 2.467% |
InnoPharmax Inc. | 5.38 Million TWD | -5762.403% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | -213.147% |
Excelsior Biopharma Inc. | 300.25 Million TWD | -5.162% |
Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | -2307.541% |
Handa Pharmaceuticals, Inc. | 7.67 Million TWD | -4016.139% |
UniPharma Co., Ltd. | - TWD | -Infinity% |
Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | 36.812% |
Alar Pharmaceuticals Inc. | 138 Thousand TWD | -228703.623% |
Winston Medical Supply Co., Ltd. | 56.05 Million TWD | -463.264% |
Mercury Biopharmaceutical Corporation | 41.66 Million TWD | -657.773% |
Bioray Biotech Co., Ltd | 65.65 Million TWD | -380.921% |
TSH Biopharm Corporation Limited | - TWD | -Infinity% |